闵行附近的人想找个玩一玩-闵行附近的人想找个玩一玩_第1页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
media coverage
Your current position: home page >> News Center >> media coverage
Taking advantage of the policy, this aircraft carrier formation in the nuclear and pharmaceutical industry has declared to be the Ali of China's nuclear medicine!
Date [16:04, June 12, 2018]【 】Times

In the second quarter of 2018, for Yantai Dongcheng pharmaceutical, it can be said that there are many good news.

 

On April 9, the national health and Family Planning Commission announced that it would release the approval right of PET-CT and other large-scale medical equipment configuration certificates. On the same day, Dongcheng pharmaceutical officially completed the acquisition of Andico, which is one of the only two PET-CT developer manufacturers in China.

 

Dean's pet-18f is widely used in pet-18f imaging. Therefore, this layout of Dongcheng pharmaceutical industry is expected to ride the free ride of policy dividend.

 

As a matter of fact, since 2015, Dongcheng pharmaceutical has been very optimistic about the prospect of radionuclide drugs, which is the market segment of radionuclide drugs, and has added sufficient power to the company's "third carriage". At present, it has acquired, controlled or participated in 6 Nuclear drug enterprises, aiming to become "Ali, Shunfeng and Huawei" in the field of radionuclide medicine.

 

▍ the industry is in a period of rapid growth, opportunities outweigh challenges

 

According to the statistics of the industry, the sales of radioactive drugs in 2016 will increase by 46.77 billion US dollars, reaching US $46.7 billion in 2016. In terms of the distribution of the global radiation market, the United States accounts for 38%, Europe accounts for 24%, and China accounts for less than 7%. The amount and variety of radioactive drugs in China is small, which has become the main bottleneck of the development of nuclear medicine in China.

 

In addition, the development of diagnostic and therapeutic drugs in radiopharmaceuticals in China is not balanced. The use of diagnostic radionuclides accounts for about 80% of the total radionuclide drug market, and the proportion of therapeutic drugs is only 20%.

 

In recent years, with the progress of nuclear medicine in China and the increasing awareness of radioactive drugs by the state and the public, the domestic radiopharmaceutical industry has developed rapidly, and the sales revenue has increased by 25% annually. It is estimated that the total amount of domestic market will reach 10 billion yuan by 2020, realizing a huge volume. With the approval of new radionuclide drugs for treatment, the development momentum of therapeutic radionuclide drugs is rapid, and the growth rate is far higher than that of diagnostic radionuclide drugs.

 

From the perspective of enterprise development, before that, there were more than 20 domestic nuclide drug manufacturers with small scale and scattered scale, weak innovation and promotion ability, and also lack of leaders; in contrast, due to the long development time of foreign radioactive drugs, advanced technology level, mostly concentrated in high-end market, domestic and foreign brands formed a certain market difference.

 

In this regard, industry insiders predict that with the increase of domestic nuclear medicine personnel training, the strengthening of system and standard construction, the improvement of quality control and safety, the increase of domestic nuclear medicine drugs and domestic nuclear medical instruments, and the emergence of new technologies and methods of nuclear medicine, China's nuclear medicine will also be widely recognized in clinical practice, and its popularity will gradually increase, with international influence Gradually increasing, radionuclide drugs will play an increasingly important clinical role.

 

In fact, in addition to liberalizing the approval right of PET-CT and other large-scale medical equipment configuration certificates, the national health and Family Planning Commission, the Ministry of industry and information technology and other ministries and commissions also contribute to the promotion of the application of radionuclide drugs. According to the public information, Shanghai Lianying film and ruishikang have developed rapidly.

 

As of the end of 2015, 239 sets of pet (CT / MR) and 370 sets of SPECT (growth rate of 11.45%) were recorded in the whole domestic nuclear medicine imaging equipment market. All these indicate that China's nuclear medicine industry is in a period of rapid growth, and the opportunities for Chinese nuclide medicine enterprises are greater than the challenges.

 

▍ "the third carriage" creates the new core competitiveness of the company

 

Seeing the development trend of the industry, Dongcheng pharmaceutical, which started with heparin API, began to actively lay out the "third carriage" of nuclear medicine plate.

 

Since 2015, the company has successively acquired the production platform for therapeutic radiopharmaceuticals represented by Yunke pharmaceutical, the R & D platform for radiopharmaceuticals represented by Yitai pharmaceutical, and the real-time labeling and distribution platform for radiopharmaceuticals represented by Shanghai Xinke. In the latest integration this year, the company successfully acquired Andico with a total of 1.6 billion yuan.

 

Among them, Yunke Pharmaceutical Co., Ltd., a subsidiary of China Nuclear Power Research and Design Institute, actively studies, designs and builds a special medical isotope production reactor (MIPR), which can produce 99Mo, 131I and 89Sr at the same time. It is of great significance to solve the shortage of medical nuclide supply in China and master the upstream resources of the industry.

 

Industry insiders pointed out that this series of integration and merger cases greatly consolidated Dongcheng pharmaceutical's leading position in the nuclear drug market.

 

Through the acquisition of Andico, Dongcheng pharmaceutical will also complete the full coverage of single photon and positron drugs, diagnostic and therapeutic drugs, and become a provider of radionuclide drugs and nuclear medicine solutions with a complete industrial chain.

 

In fact, according to the annual report of Dongcheng pharmaceutical in 2017, nuclear medicine, as the "third carriage", has become the strongest driving force for the company's performance growth. In 2017, the company's operating revenue was 1.6 billion yuan, with a net profit of 173 million yuan, a year-on-year increase of 31.83%. Among them, the business income of nuclide medicine accounts for 36.97% of the company's business income.

 

The analysis from the third-party securities companies shows that under the complicated market situation, Dongcheng pharmaceutical can actively adapt to the new normal of the industry. On the one hand, the three major businesses of "API, general preparation and nuclear medicine" have maintained the development momentum of exceeding the growth rate of their respective sub sectors; on the other hand, the company actively promotes the extension acquisition in the field of nuclear medicine and continues to integrate domestic nuclear medicine Pharmaceutical resources, to create a new core competitiveness of the company.

 

Securities companies predict that in 2018, the company will actively promote its leading edge in the field of nuclear medicine and will continue to expand.

It aims to become "Ali, Huawei and SF" in the nuclear drug industry.

 

With the inclination of policies and regulations and the construction of talent team, China's nuclear drug industry has been looking forward to the emergence of "black horse" or even the leader. With the policy liberalization, the installed capacity of PET-CT in medical institutions has increased, and the demand for PET-CT developer will be further increased. Undoubtedly, Dongcheng pharmaceutical will fully benefit from the market expansion and become the industry leader.

 

At present, Dongcheng pharmaceutical has taken the nuclear medicine industry as the company's strategic focus in the next 10 years. Its strategic policy is to "set foot in the upstream, integrate the downstream, and lay out the frontier", and has made a bold statement that "Dongcheng pharmaceutical will become Ali in the field of nuclear medicine".

 

▍ "secret weapon" -- Nuclear Pharmacy

 

In order to achieve the above goals, Dongcheng pharmaceutical is strategically implementing a "secret weapon" - nuclear pharmacy. Due to the limitation of the short half-life of radionuclide drugs, it is necessary to set up a nationwide distribution center for the production, management, distribution and service of radioactive instant labeling drugs or positron nuclide drugs.

 

The nuclear pharmacy was initially initiated by Dongcheng Xinke company in China to provide radioactive drugs to medical institutions. In 2016, Dongcheng Pharmaceutical Co., Ltd. acquired Dongcheng Xinke

In addition, the latter has 7 radioactive drug production bases in China. The newly acquired Andico has seven nuclear pharmacies in use. Combined with the number of self built companies, Dongcheng pharmaceutical has 30 nuclear pharmacies in China.

 

In the next three years, Dongcheng pharmaceutical will build another 30 nuclear pharmacies on the basis of the existing 30 nuclear pharmacies. The company hopes that through solid development, Dongcheng will be built into Ali of nuclear medicine on the platform of nuclear medicine, Huawei of nuclear medicine in terms of innovation of nuclear medicine, Shunfeng of nuclear medicine in terms of logistics of nuclear medicine, and the king of nuclear medicine subdivision field of Dongcheng pharmaceutical industry. A nuclear powered aircraft carrier formation, "Dongcheng nuclear medicine", has set sail for the world.

 
Last article:
Next:
contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
Address: No.7 Changbaishan Road, Yantai Development Zone, Shandong Province
Copyright 2014 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All Rights Reserved Lu ICP Bei 18035060-1